GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Scaled Net Operating Assets

Celadon Pharmaceuticals (LSE:CEL) Scaled Net Operating Assets : 0.70 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Celadon Pharmaceuticals's operating assets for the quarter that ended in Dec. 2023 was €9.24 Mil. Celadon Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2023 was €1.54 Mil. Celadon Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was €11.03 Mil. Therefore, Celadon Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.70.


Celadon Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Celadon Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celadon Pharmaceuticals Scaled Net Operating Assets Chart

Celadon Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
0.97 1.03 - - 0.51

Celadon Pharmaceuticals Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial - 0.93 0.40 0.47 0.70

Competitive Comparison of Celadon Pharmaceuticals's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Celadon Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celadon Pharmaceuticals's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celadon Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Celadon Pharmaceuticals's Scaled Net Operating Assets falls into.



Celadon Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Celadon Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(9.242-1.536)/15.236
=0.51

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.703 - 1.461
=9.242

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.011 - 5.389 - 0.086
=1.536

Celadon Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(9.242-1.536)/11.025
=0.70

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.703 - 1.461
=9.242

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.011 - 5.389 - 0.086
=1.536

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celadon Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Celadon Pharmaceuticals (LSE:CEL) Business Description

Traded in Other Exchanges
N/A
Address
32-33 Cowcross Street, London, GBR, EC1M 6DF
Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines